MASP-2 inhibitors for IgA nephropathy (EvolVeritas)

N/A

Report date: 2025/04/30 09:58:10

Base Information

Drug NameMASP-2 inhibitors for IgA nephropathy (EvolVeritas)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionMannan-binding lectin serine protease 2 inhibitors
TargetsMannan-binding lectin serine protease 2
Therapy Area/IndicationsGlomerulonephritis, IGA
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryHungary
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEvolVeritas Biotechnology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEvolVeritas Biotechnology Ltd
Inactive CompaniesN/A
Active IndicationsGlomerulonephritis, IGA
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A